Implications of Amyloid Pathology
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00900770|
Recruitment Status : Unknown
Verified December 2009 by National Institute on Aging (NIA).
Recruitment status was: Recruiting
First Posted : May 13, 2009
Last Update Posted : December 29, 2009
|Condition or disease|
There is compelling evidence supporting amyloid as one of the key pathologic agents in AD. Autopsy studies suggest the amount and location of fibrillar amyloid deposition does not relate strongly to the degree and type of clinical impairment, compared to tau pathology and neuronal loss. A substantial percentage of individuals known to be cognitively intact prior to death demonstrate significant amyloid pathology at autopsy. PIB-PET studies of older normal individuals have also demonstrated significant amyloid deposition in substantial percentages.
This study will test the hypothesis that amyloid is associated with synaptic dysfunction and neuronal damage. While some individuals are able to compensate for amyloid-related toxicity for an extended time period, sensitive imaging and neuropsychological markers will reveal that normal subjects with evidence of high amyloid burden do demonstrate evidence of abnormality consistent with prodromal AD.
The study will use a combination of functional, structural, and cognitive measures to detect early effects of amyloid deposition, and will utilize PIB retention in order to characterize the relationship of amyloid to neuropsychological and imaging markers of prodromal AD. The relationship of PIB retention to genetic, plasma and cerebrospinal fluid (CSF) biomarkers will be explored. These preliminary data will be used to determine whether asymptomatic older individuals with high amyloid burden will subsequently manifest cognitive impairment and eventually progress to clinical AD. When completed, this project will either provide evidence that the presence of amyloid deposition is a useful biomarker for incipient AD or raise the possibility that amyloid deposition examined in isolation is insufficient to predict early symptoms and progression of AD.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Implications of Amyloid Deposition in Clinically Normal Older Individuals|
|Study Start Date :||November 2008|
|Estimated Primary Completion Date :||March 2014|
|Estimated Study Completion Date :||March 2014|
PIB positive, cognitively normal individuals with foci of elevated PIB retention in cortical regions typically affected in AD
PIB negative, cognitively normal individuals without amyloid deposition
- Pittsburgh Compound B (PiB) and F-18 fluorodeoxyglucose (FDG) PET Scan [ Time Frame: at 1 month ]
- Cognitive and functional assessments [ Time Frame: Baseline and annually for 5 years ]
- Lumbar Puncture (optional) [ Time Frame: Baseline ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900770
|United States, Massachusetts|
|Brigham and Women's Hospital||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: Kelly O'Keefe 617-726-6212 email@example.com|
|Contact: Meghan Frey 617-732-8085 firstname.lastname@example.org|
|Principal Investigator: Reisa A. Sperling, MD|
|Sub-Investigator: Keith A. Johnson, MD|
|Principal Investigator:||Reisa Sperling, MD||Director of Clinical Research, Memory Disorders Unit, Brigham and Women's Hospital|